Deucrictibant
Hereditary Angioedema With Normal C1Inh
Explore 1 assets in Hereditary Angioedema With Normal C1Inh →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Pharvaris Netherlands B.V.
Modality
Small molecule
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05396105CT.gov Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema | — | Enrolling By Invitation | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hereditary Angioedema With Normal C1Inh
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Deucrictibant (this asset) | Pharvaris Netherlands B.V. | P2/3 | B · 57 |
Other indications for Deucrictibant
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hereditary Angioedema With C1Inh Deficiency | — | P3 | BBB · 78 |
| Hereditary Angioedema | — | P3 | BBB · 76 |
| Hereditary Angioedema Type 1 | — | P3 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Deucrictibant in Hereditary Angioedema With Normal C1Inh. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/deucrictibant-hereditary-angioedema-with-normal-c1inh
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →